R&D

Data Science Company for Next Generation Drug Discovery

OVERVIEW

Promising candidate substances come from high quality data.

Drug

We Provide a roadmap to understand the overall drug characteristics and mechanism of action, such as drug target prediction, candidate substance prediction, drug repositioning, new indication discovery, and side-effect prediction.

Tech

Proprietary algorithms and integrated platform technologies
  • BEAR: Bioactive compound Enrichment by Assay Repositioning (Korean & U.S patent registration)
  • BACoN: BioActivity based Compound Network (Korean patent registration)
  • CSgator: Compound Set Navigator
    (J. Cheminformatics 2019, csgator.ewha.ac.kr)
  • KMAP Express (kmap.kaipharm.com)
  • In addition, several research papers and patent applications are currently in preparation.

Data

Customized data production
+ large-scale data mining
  • ~3,000 approved drugs’ transcriptomic profiling
    (in-house production)
  • ~40,000 compound libraries’ transcriptomic profiling
  • ~600 diseases’ transcriptomic profiling
  • ~100M compounds information
  • ~200M compounds’ bioactivities
  • ~10M compounds-target interactions
  • ~1.57M drug-disease interactions
  • ~1,000 biological pathway information
    (Last updated Nov. 2021)

01. Drug

We Provide a roadmap to understand the overall drug characteristics and mechanism of action, such as drug target prediction, candidate substance prediction, drug repositioning, new indication discovery, and side-effect prediction.

02. Tech

Proprietary algorithms and integrated platform technologies

  • BEAR: Bioactive compound Enrichment by Assay Repositioning (Korean & U.S patent registration)
  • BACoN: BioActivity based Compound Network (Korean patent registration)
  • CSgator: Compound Set Navigator
    (J. Cheminformatics 2019, csgator.ewha.ac.kr)
  • KMAP Express (kmap.kaipharm.com)
  • In addition, several research papers and patent applications are currently in preparation.

03. Data

Customized data production
+ large-scale data mining

  • ~3,000 approved drugs’ transcriptomic profiling
    (in-house production)
  • ~40,000 compound libraries’ transcriptomic profiling
  • ~600 diseases’ transcriptomic profiling
  • ~100M compounds information
  • ~200M compounds’ bioactivities
  • ~10M compounds-target interactions
  • ~1.57M drug-disease interactions
  • ~1,000 biological pathway information
    (Last updated Nov. 2021)